Gilead Sciences (NASDAQ:GILD) slips 3% premarket
on modest volume on reports that the second study of remdesivir in
China, the one in mild-to-moderately ill COVID-19 patients, has been
suspended.
The trial in severely ill patients was terminated earlier due to low enrollment.
Update: The second study was also
suspended for low enrollment. RBC’s Brian Abrahams believes that
preliminary results were probably inconclusive since a relatively high
number of patients (n=237) had been enrolled, adding that the
probability that remdesivir shows substantial efficacy in COVID-19 is a
coin toss.
https://seekingalpha.com/news/3560849-gilead-slips-on-suspension-of-second-remdesivir-study-in-china
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.